Online inquiry

IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5405MR)

This product GTTS-WQ5405MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD2 gene. The antibody can be applied in Psoriasis, severe chronic plaque research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001328609.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 914
UniProt ID P06729
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ5405MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3885MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BCD-100
GTTS-WQ8710MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ2572MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 479
GTTS-WQ10567MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY­3074828
GTTS-WQ2535MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 477
GTTS-WQ15455MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA U3-1287
GTTS-WQ7643MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GEN-1029
GTTS-WQ7348MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FPA-150
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW